15 drugs jostle for November PBS listings
Among the 15-strong list are nine drugs vying to become the first to secure subsidy after being recommended at the PBAC's July 2026 meeting
Among the 15-strong list are nine drugs vying to become the first to secure subsidy after being recommended at the PBAC's July 2026 meeting
The TGA has handed out eight orphan drug designations in the past quarter, with three of them targeting the same kidney disease.
One submission withdrawn, a couple of newcomers join the list and a potentially eye-opening DUSC analysis deferred as PBAC readies for its next meeting in a fortnight
A bitter court battle is heating up with two companies now accusing each other of misleading advertising over claims about side effects and speed of absorption
Medicines Australia has named two high-profile company leaders as the newest additions to the Board, after Country Leadership changes mid-year resulted in departures
A high-profile former Senior Health Department official turned patient advocate has called on the pharmaceutical industry to force the Government to take HTA reform seriously by withholding all submissions from the PBAC
Two out of three companies hoping to cut a path to a broad listing were told the preliminary info they provided didn't cut it, according to outcomes from September's Intracycle Meeting
A second company has registered a copycat of a cancer drug across all tablet blister strengths, turning up the heat on the originator brand
A report released by the ATO has revealed the total income declared in Australia for all pharmas who brought in at least a hundred million dollars. See the list
After 30 years working in innovative medicine companies, the decision for Nikki Lorenz to become a champion of the generics and biosimilars industry was a surprisingly easy one
While this pharma has staved off a potentially hefty fine, it has agreed to a tough, legally binding agreement after an EU antitrust case
Recognised as a Great Place to Work for the fifth time, this company blitzed the benchmarks across four measures with a standout result for celebrating special events.
Five companies have splashed cash on new assets to build out their current portfolios, with one hoping a Virtual Human AI platform will uncover transformative therapeutics
Product information updates for two jabs after reports of incorrect preparation and administration, which may result in the recall of patients for re-vaccination
The PBAC has updated the guidelines for pharmas seeking multi-cancer listings, looking for information beyond the clinical
Following reports of eight deaths overseas, allegations trial results were manipulated plus regulatory action in the UK and Europe, this drug is coming off the market
A strategy to protect market share for this oncology juggernaut has run into a major roadblock overseas and the same legal hurdle could hit Australia too
GSK's Australian Country Leader Andrew Thomas tells how being open to 'taking a shot' created a global high-flying career and offers tips on how pharma professionals can get ahead, in a new book called Work Fame
A US company is ramping up its Australian commercialisation efforts for a gene therapy that won the Best Product for Orphan Disease at the 2026 Prix Galien UK Awards
Exactly one year after the late Professor challenged Australia to bring the same ambition to brain cancer that helped transform advanced melanoma, advocates are back at Parliament House
A UCB-sponsored report into the failings of paediatric medicine funding was launched in Parliament House today, attended by the heads of the Standing Committee on Health
It's been a tough few years in pharma but this Australian recruitment expert warns that staying put in your current role just for job security is riskier than you think
This company has two generics ready to launch but has agreed to hold off ahead of a court hearing next year in which a franchise worth $170M will be challenged
Pioneering contributions to help eliminate malaria has earned this scientist Novo's coveted Young Women in Science Award plus $50K to continue her research
Talent movements across industry include a new role after redundancy, a move to a new country and leaving a company after 18 years